Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 1, 2012, Pages 45-50

  Lal, Lincy S ^a   Byfield, Stacey Dacosta ^d   Chang, Eric L ^a   Franzini, Luisa ^c   Miller, Lesley Ann ^e   Arbuckle, Rebecca ^b   Reasonda, Liezl ^a   Feng, Chun ^b   Adamus, Andrea ^b   Swint, John Michael ^a  

^a Ingenix Consulting Healthcare   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d Health Economics and Outcomes I3 Innovus   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

cost effectiveness study; cost utility study; stereotactic radiosurgery; time trade off; whole brain radiation therapy

Indexed keywords

ADULT; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION SUPPORT SYSTEM; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; STEREOTACTIC RADIOSURGERY; SURGICAL PATIENT; SURVIVAL TIME; WHOLE BRAIN RADIOTHERAPY;

ADULT; AGED; BRAIN NEOPLASMS; COST-BENEFIT ANALYSIS; CRANIAL IRRADIATION; DIRECT SERVICE COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RADIOSURGERY; TEXAS;

EID: 84856297823     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182005a8f     Document Type: Article

References (20)

1. Chang E, Wefel J, Hess K, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial. Lancet Oncol. 2009;10:1037-1044.
2. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy versus stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483-2491. (Pubitemid 43854963)
3. Taphoorn MJB, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol. 2005;6:937-944. (Pubitemid 41685226)
4. Fairclough DL. Design and Analysis of Quality of life Studies in Clinical Trials. London: Chapman and Hall/CRC 2002
5. Scott CB. Quality-adjusted survival analysis of malignant glioma patients. Control Clin Trials. 1997;18:277-285. (Pubitemid 27337017)
6. Marko NF, Weil RJ. Radiotherapy: neurocognitive considerations in the treatment of brain metastases. Nat Rev Clin Oncol. 2010;7:185-186.
7. Drummond MF, O'Brien B, Stoddard GL, et al. Methods for the Economic Evaluatin of Health Care Programmes. 2nd ed. New York Oxford University Press, Inc; 1997
8. Producer Price Index Industry Data: http://data.bls.gov/cgi-bin/ surverymost last accessed on March 30, 2010.
9. Methodology for computing estimated costs. Division of Clinical Revenue and Reimbursement. The University of Texas M.D. Anderson Cancer Center. Personal communication with Robin Simmons on August 5, 2009.
10. Torrance GW. Preferences for health states: a review of measurement methods. Mead Johnson Symp Perinat Dev Med. 1982;20:37-45.
11. Stiggelbout AM, Kiebert GM, Kievit J, et al. The "utility" of time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidemiol. 1995;48:1207-1214.
12. Van Nooten F, Brouwer W. The influence of subjective expectations about length and quality of life on time trade-off answers. Health Econ. 2004;13:819-823. (Pubitemid 39136906)
13. Van Nooten FE, Koolman X, Brouwer WB. The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Econ. 2009;18:549-558.
14. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci. 2004;7:43-49. (Pubitemid 39024064)
15. Wong Y, Meropol NJ, Speier W, et al. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009;115:2081-2091.
16. Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer. 2009;45:1397-1406.
17. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33:583-590. (Pubitemid 23161878)
18. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494-500. (Pubitemid 20067825)
19. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29:711-717. (Pubitemid 24241310)
20. Kattan MW, Fearn PA, Miles BJ. Time trade-off utility modified to accommodate degenerative and life-threatening conditions. Proc AMIA Symp. 2001;304-308.